Novartis AG (LON:0K9E)

Market Cap	203.63B
Revenue (ttm)	41.94B
Net Income (ttm)	10.71B
Shares Out	n/a
EPS (ttm)	5.43
PE Ratio	19.02
Forward PE	16.41
Dividend	2.61 (1.89%)
Ex-Dividend Date	Mar 12, 2025

Volume	269
Average Volume	1,690
Open	142.48
Previous Close	141.38
Day's Range	141.89 - 142.80
52-Week Range	97.51 - 143.23
Beta	0.45
RSI	69.97
Earnings Date	Feb 4, 2026

About Novartis AG

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocy...

• Industry: Pharmaceutical Preparations
• Founded: 1996
• Employees: 75,883
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0K9E

Financial Performance

In 2024, Novartis AG's revenue was $51.72 billion, an increase of 10.85% compared to the previous year's $46.66 billion. Earnings were $11.94 billion, a decrease of -19.59%.

Financial numbers in USD